Scpharmaceutical Stock Price, News & Analysis

scPharmaceuticals Inc. (SCPH) has completed all testing for FUROSCIX and plans to re-submit its New Drug Application (NDA) by April 15, 2022, aiming for a Q4 2022 commercial launch. The company ended Q4 2021 with $75.5 million in cash and investments, down from $105.3 million in 2020. It reported a net loss of $7.3 million for Q4 2021, slightly better than the $7.8 million loss in Q4 2020. R&D expenses increased to $4.5 million, while G&A expenses decreased to $2.2 million. The company forecasts a net loss of $43 to $48 million for 2022.

BURLINGTON, Mass., Feb. 16, 2022 – scPharmaceuticals (Nasdaq: SCPH) announced that John Tucker, CEO, will present at the 42nd Annual Cowen Healthcare Conference on March 8 at 1:30 PM EST. The company focuses on optimizing therapies and reducing healthcare costs through innovative products, particularly in outpatient care for heart failure and infectious diseases. A live webcast of the presentation will be available on the company's website. For more information about scPharmaceuticals, visit www.scpharmaceuticals.com.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 4:20pm EDT. The presentation aims to highlight the company's innovative approach to developing products that reduce healthcare costs and improve patient care. scPharmaceuticals focuses on outpatient care for acute conditions, particularly in heart failure and infectious diseases. A live webcast will be available on their investor relations website.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that John Tucker, president & CEO, will participate virtually in two upcoming investor conferences. The first event is the 11th Annual LifeSci Partners Corporate Access Event 2022, scheduled for January 5-7, 2022. Attendees can register and request one-on-one meetings via the provided link. The second event is the H.C. Wainwright Virtual BioConnect 2022 Conference, taking place from January 10-13, 2022, with a webcast available on-demand starting January 10 at 7am EST.

scPharmaceuticals Inc. (SCPH) announced successful testing of commercial devices required by the FDA for FUROSCIX. The NDA resubmission is expected in Q1 2022 due to COVID-19-related delays, but this will not affect the anticipated Q4 2022 launch, if approved. The company ended Q3 2021 with $85 million in cash, projecting sufficient funds into 2023. The net loss for Q3 2021 was reduced to $6.6 million compared to $9 million the previous year. The 2021 net loss guidance has been revised down to $29-31 million.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that its CEO, John Tucker, will present at the Jefferies London Healthcare Conference on November 17, 2021, at 9:25 EDT / 2:25 GMT. The event will take place in-person from November 16-17 and virtually on November 18-19. A live webcast of the presentation will be available under the Investor Relations section on the Company's website.

scPharmaceuticals focuses on developing products that enhance outpatient care for acute conditions, particularly in heart failure and infectious diseases.

scPharmaceuticals (SCPH) reported positive results from the FREEDOM-HF clinical trial showing significant reductions in heart failure-related healthcare costs for patients treated with FUROSCIX®. The study, presented at the HFSA Annual Meeting, found 30-day HF-related costs were $17,753 lower for FUROSCIX patients compared to a historical comparator group. The company plans to resubmit its New Drug Application (NDA) for FUROSCIX in Q4 2021, backed by over $90 million in financing. No serious adverse events were recorded during the study.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that President & CEO John Tucker will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available on-demand starting at 7am EDT on September 13. scPharmaceuticals focuses on developing products aimed at optimizing infused therapies, advancing patient care, and reducing healthcare costs, particularly in heart failure and infectious disease treatments.

scPharmaceuticals (SCPH) announced progress in its FUROSCIX NDA resubmission, aligning with the FDA, requiring no additional clinical data or device changes. Targeting Q4 resubmission, the company presented positive FREEDOM-HF study results, showing a $17,753 reduction in heart failure costs per patient. Ending Q2 with $90.2 million in cash, the firm is poised to fund operations through 2023, lowering its 2021 net loss guidance to $30-34 million. The FREEDOM-HF data supports potential market adoption if FUROSCIX is approved.